Healthcare
CareDx Inc(CDNA)
Live Price
Offline$26.18
+11.50% today
1Y Change
+37.00%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $1.07B
- Revenue Growth
- +13.8%
- EPS Growth
- -140.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CareDx Inc (CDNA) is a Healthcare stock with a market cap of $1.07B and listed on NASDAQ. The stock last traded around $26.18 and up 37.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +13.8%, EPS growth of -140.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.8%, EPS -140.0%, free cash flow +14.4% with operating margin -3.2% and ROIC -4.0%. Valuation is more restrained than many high-expectation growth names at price/sales 2.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CDNA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.8% vs +7.6% peer median
Operating Margin
Below sector median
-3.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +13.8% and EPS is at -140.0%, with operating margin around -3.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +0.0% | +0.7% | +9.1% |
2026 Feb 24, 2026 | -502.0% | -4.1% | -2.3% | -7.3% |
2025 Nov 4, 2025 | +115.4% | +13.8% | +15.6% | +29.8% |
Benchmark Edge
CDNA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CDNA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CDNA Max Drawdown
-43.92%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CDNA and SPY.
Company Overview
CareDx Inc
NASDAQ
CareDx Inc. is a leading precision medicine company that discovers, develops, and commercializes clinically differentiated diagnostic solutions for transplant patients and caregivers. It specializes in genomics-based testing services, including AlloSure Kidney and AlloSure Heart for donor-derived cell-free DNA surveillance in kidney and heart transplant patients, AlloMap Heart as a gene expression test for heart transplants, and AlloSure Lung for lung transplants. The company also provides high-quality lab products like HLA typing solutions such as AlloSeq Tx, Olerup SSP, and AlloSeq cfDNA to improve donor-recipient matching for organs and stem cells. Complementing these, CareDx Inc. offers digital transplant solutions through platforms like Ottr for patient surveillance and EMR integration, XynManagement for quality improvement and care coordination, and mobile apps such as AlloCare and Transplant Hero for medication adherence and health monitoring. Operating primarily in the healthcare sector with a focus on testing services, products, patient solutions, and pharma services, CareDx Inc. supports transplant centers, clinicians, and biopharma partners across the pre- and post-transplant journey. Founded in 1998 and headquartered in Brisbane, California, it plays a key role in advancing transplant outcomes through non-invasive molecular testing and innovative technologies.
- Leadership
- Mr. John Walter Hanna Jr.
- Employees
- 644
- Street Address
- 8000 Marina Boulevard, Brisbane
- Mailing
- South San Francisco, CA, 94005
- Region
- South San Francisco, CA, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 100.2
- Price/Sales
- 2.6
- Price/Book
- 3.4
Growth
- Revenue
- +13.8%
- EPS
- -140.0%
- Free Cash Flow
- +14.4%
Profitability
- Gross Margin
- 68.6%
- Operating Margin
- -3.2%
- Net Margin
- -2.0%
- ROE
- -2.6%
- ROIC
- -4.0%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 3.40
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.